An Open-Label Extension Of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy

Trial Profile

An Open-Label Extension Of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 26 Aug 2016 New trial record
    • 08 Aug 2016 According to a Pfizer media release, results of pooled post hoc analysis from this and other two trials (Profiles 19933 and 252196) were published online in Amyloid: The Journal of Protein Folding Disorders.
    • 08 Aug 2016 Results of pooled post hoc analysis from this and other two trials (Profiles 19933 and 252196) published in a Pfizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top